pharmaphorum8 天
Synlogic preps phenylketonuria drug for phase 3 after mid-stage win
PKU is a rare genetic disease that manifests at birth and is marked by an inability to break down phenylalanine (phe), an amino acid that is commonly found in many foods. Left untreated ...
pharmaphorum1 年
Synlogic shuts down after PKU drug fails phase 3 trial
PKU is a rare genetic disease that manifests at birth and is marked by an inability to break down phenylalanine (phe), an amino acid that is commonly found in many foods. Left untreated ...